A Phase 1b Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Phase 1
24
about 1.8 years
18+
3 sites in AL, IN, NY
What this study is about
Researchers are testing a new treatment called DISC-3405 for people with sickle cell disease. The trial will evaluate the safety, tolerability, and how the drug works in the body at different doses.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take DISC-3405
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Safety and tolerability of DISC-3405 administration in participants with SCD
Secondary: Apparent clearance (CL/F) following the first dose, Area under the plasma concentration versus time curve extrapolated to infinity (AUC∞) following the first dose, Elimination half-life (T1/2el) following the first dose, Maximum plasma concentration (Cmax) following the first dose, Pharmacodynamic (PD) properties of DISC-3405 in participants with SCD by change from baseline for Lactate Dehydrogenase (LDH), Pharmacodynamic (PD) properties of DISC-3405 in participants with SCD by change from baseline for Red Blood Cell Count (RBC), Pharmacodynamic (PD) properties of DISC-3405 in participants with SCD by change from baseline for bilirubin (direct and indirect), Pharmacodynamic (PD) properties of DISC-3405 in participants with SCD by change from baseline for hematocrit (HCT)